DATA GRAPHICS | Data Byte
Etrasimod may have best-in-class data for ulcerative colitis
Pfizer planning regulatory submissions for S1PR1 inhibitor this year
May 25, 2022 12:45 AM UTC
Detailed data from two Phase III studies of Pfizer’s etrasimod suggested the S1PR1 inhibitor may be best in class for ulcerative colitis.
If it were to reach the market for ulcerative colitis, etrasimod from Pfizer Inc. (NYSE:PFE) would compete with approved S1PR1 inhibitor Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY). Data from two Phase III trials reported Tuesday suggest that etrasimod may have the upper hand on efficacy...